Takara Bio Inc. provided earnings guidance for the six months ending September 30, 2020 and full year ending March 31, 2021. For the six moths, the company expects net sales of JPY 16,870 million, operating profit of JPY 2,500 million, net income attributable to the owners of the parent of JPY 1,248 million and net income of JPY 10.37 per share. For the year, the company expects net sales of JPY 39,600 million, operating profit of JPY 6,500 million, net income attributable to the owners of the parent of JPY 4,000 million and net income of JPY 33.22 per share.